




Online Supplementary Information



CD8⁺ T cells specific for the islet autoantigen IGRP are restricted in their T cell receptor chain usage

Yannick F. Fuchs, Anne Eugster, Sevina Dietz, Christian Sebelefsky, Denise Kühn, Carmen Wilhelm, Annett Lindner, Anita Gavrigan, Jan Knoop, Andreas Dahl, Anette-G. Ziegler and Ezio Bonifacio


Supplementary Figures:




Supplementary Fig. S1: Identification and TCR repertoire analysis of Flu MP₅₈₋₆₆-specific CD8⁺ T cells. (a) Representative FACS plots of PBMC samples of 3 healthy and one donor with long standing type 1 diabetes (T1D-1) stained with HLA-A2 multimers loaded with control peptide (HLA-A2₁₄₀₋₁₄₉; top row) or Flu MP₅₈₋₆₆ (bottom row). Cells are gated on CD8 and 10⁵ CD8⁺ T cells are depicted in each plot. (b) TCR repertoire analysis upon TCR α - and TCR β -chain sequencing of Flu MP₅₈₋₆₆ specific CD8⁺ T cells isolated as single cells from samples shown in A. Pieces of pie charts represent cells with the same TCR α -/TCR β -chain combination (clonotypes; upper row), TCR α -chain (middle row) or TCR β -chain (middle row). Numbers of analyzed cells are indicated. Shades of gray represent private clonotypes or TCR chains, colors indicate sharing among individuals. (c) Frequencies of TRAV, TRAJ, TRBV and TRBJ genes detected in unique Flu MP₅₈₋₆₆ specific clonotypes (n=90) identified in donors shown in A. TRAV, TRAJ, TRBV and TRBJ gene analysis reveals preferential usage of *TRBV19* and *TRBJ2-7* in TCR β -chains and *TRAJ42* in TCR α -chains of Flu MP₅₈₋₆₆ specific CD8⁺ T cells.




Supplementary Fig. S2: Phenotypic characterization of IGRP₂₆₅₋₂₇₃-specific CD8⁺ T cells in healthy adults and patients with long standing type 1 diabetes. (a) Analysis of CCR7 and CD45RA expression on IGRP₂₆₅₋₂₇₃-specific CD8⁺ T cells in healthy donors (n=10) and patients with long standing type 1 diabetes (n=10). PBMC were stained without (w/o) or with either control peptide (HLA-A2₁₄₀₋₁₄₉) or IGRP₂₆₅₋₂₇₃ loaded multimers. Staining of PBMC samples spiked with IGRP₂₆₅₋₂₇₃ specific CD8⁺ T cell clones served as controls (upper row). Plots of multimer stainings show cells in the CD8 gate and at least 5 x 10⁴ events are shown. Plots of CCR7/CD45RA expression show all events of the ancestor gate and frequencies of naïve (CD45RA⁺CCR7⁺) cells are indicated. For patients with long standing type 1 diabetes representative FACS plots of donors with high (T1D-1 and T1D-3) and low frequencies (T1D-6-13) of IGRP₂₆₅₋₂₇₃ specific CD8⁺ T cells are shown. (b) Data graph summarizing the frequencies of naïve (CCR7⁺CD45RA⁺; open symbols) and memory (CCR7⁺CD45RA⁻, CCR7⁻CD45RA^{+/+}; filled symbols) IGRP₂₆₅₋₂₇₃-specific CD8⁺ T cells of adult healthy donors and patients with long standing type 1 diabetes shown in (a).




Supplementary Fig. S3: Persistence of IGRP₂₆₅₋₂₇₃ specific CD8⁺ T cells and clonotypes in T1D-1. (a) Representative FACS plots of multimer stainings performed on PBMC samples taken at three independent timepoints. PBMC samples were stained with HLA-A2 multimers loaded with control peptide (HLA-A2₁₄₀₋₁₄₉; top row) or IGRP₂₆₅₋₂₇₃ (bottom row). Plots show 10⁵ cells in the CD8 gate. (b) TCR repertoire analysis upon TCR α - and β -chain sequencing of IGRP₂₆₅₋₂₇₃ specific CD8⁺ T cells isolated as single cells from samples of three individual timepoints. Pieces of pies represent distinct clonotypes and same colors represent same clonotypes. Numbers of cells for which parallel TCR α - and β -chain information was obtained for each individual timepoint are indicated.




Supplementary Figure S4: Retrieval of IGRP α1 and IGRP α2 via TCR α-chain next generation sequencing. cDNA libraries of bulk sorted CD3⁺CD8⁺ T cells from donors T1D-1, T1D-2, T1D-3 were screened for message of the dominant IGRP₂₆₅₋₂₇₃-specific TCR α-chains IGRP α1 and IGRP α2 shown in Figure 1C (and depicted in red and yellow). Bars in the data graph represent frequencies (y axis) of the respective messages among all TCR α-chain messages in a given library.



Supplementary Fig. S5: Next generation sequencing read frequencies of TCR α-chain CDR3 harboring the SGGSNYKLT motif in CD8⁺ T cell libraries. Naïve (CCR7⁺CD45RA⁺; open symbols) and memory (CCR7⁺CD45RA⁻, CCR7⁻CD45RA⁺; filled symbols) CD8⁺ T cells of healthy donors (n=14, green symbols) or donors with multiple islet autoantibodies (AAb+; n=13; orange symbols) or recent onset type 1 diabetes (n=8; red symbols) were flow sorted from PBMC, their RNA extracted, individual cDNA libraries prepared and processed via next generation sequencing. TCR α-chain sequences were extracted and screened for those harboring the SGGSNYKLT motif. Frequencies of motif containing sequences in individual libraries are shown. Lines indicate median values.



Supplementary Fig. S6: Gene transcription profiles of Flu MP₅₈₋₆₆ and IGRP₂₆₅₋₂₇₃ specific CD8⁺ T cell clones. Clones were single cell-sorted and processed for multi-parameter gene expression analysis as described in supplementary methods below. The profiles for 42 Flu MP₅₈₋₆₆-specific cells of clone 7 and 72 IGRP₂₆₅₋₂₇₃-specific cells of clones 16, 17, and 22 are shown. **(a)** Heatmaps showing expression profiles. Genes are ordered left to right according to their overall significance for comparisons between cells from the two groups using the Hurdle model. Each row represents an individual cell. Cells are ordered according to their expression of the genes *GZMH*, *TBX21*, *CD52* and *TNF* **(b)** Bar chart showing p-values for gene expression comparisons between FluMP₅₈₋₆₆- and IGRP₂₆₅₋₂₇₃-specific CD8⁺ T cell clones using a continuous (left panel), discontinuous (middle) and the Hurdle (right) model. **(c)** Violin plots showing the distribution of Ct expression values for genes differentially expressed ($P < 0.01$) in Flu MP₅₈₋₆₆- and IGRP₂₆₅₋₂₇₃-specific cells in (A). The proportion of cells expressing the gene ranges from light blue (0%) to dark blue (100%).



Supplementary Fig. S7: Gating strategy for the analysis and single cell sorting of antigen-specific CD8⁺ T cells. Representative FACS plots for the gating of multimer positive CD8⁺ T cells and the analysis of CCR7 and CD45RA expression are shown. Forward and side scatter channels were used to gate on lymphocytes and to exclude doublet cells. Live/Dead cell marker staining was used to gate on viable cells. Dump marker (CD4, CD14, CD16, CD19, CD56, CD335) were used to simplify gating on CD8^{high} T cells and subsequently multimer positive cells.

Supplementary Table S1: CD8⁺ T cell clonotypes and TCR chains identified in multimer isolated antigen-specific single cells. TCR sequencing information of the CDR3 region retrieved from 775 antigen-specific CD8⁺ T cells is listed. Rows are ordered according to the peptide antigen the cells were directed against, the individuals they were obtained from, the number of cells detected with a specific TCR information (enriched: information retrieved from more than one cell; single: information retrieved from one cell) and the completeness of TCR information, i.e paired TCR α / TCR β information followed by TCR α information only, TCR β information only. TCR names are given to unique TCR α / TCR β pairs (clonotypes). TCR α and TCR β CDR3 names are given to unique TCR α and TCR β CDR3 sequences, respectively. Identical TCR CDR3 sequences present in several rows are marked (colored cells), TCR TRAV, TRAJ, TRBV and TRBJ genes used in more than 20 percent of clonotypes directed against the Flu MP₅₈₋₆₆ or IGRP₂₆₅₋₂₇₃ antigen are marked with colored font. Inter-individual sharing of sequences or previous description of sequences by others¹⁻⁵ are remarked under comments. N/A=sequence information not available; T1D=type 1 diabetes patient; HC=healthy control donor; RO=recent onset

Please note: For facilitated extraction and further use of the sequence data an Excel-file of Supplementary Table S1 can be provided by the authors on request.

Antigen	Donor	TCR name (clonotype)	TRBV	TRBJ	TRBD	TCRβ CDR3 sequence	TCRβ CDR3 name	TRAV	TRAJ	TCRα CDR3 sequence	TCRα CDR3 name	Number cells	Comments	
FluMP58-66	T1D-1	FLUMP58_T1D-1_1	19*01	2-3*01	2*01	CASSGGGSKKTQF	FLU β53	29/DV5*01	42*01	CAASAGGGSQGNLIF	FLU α56	3	Enriched	
		FLUMP58_T1D-1_2	19*01	2-7*01	1*01	CASRRGRSSYEHYF	FLU β54	26-1*01	53*01	CIVSVLQWGSQGNLIF	FLU α57	2		
		FLUMP58_T1D-1_3	19*01	2-1*01	2*01	CASSIRSLDEQFF	FLU β55	25*01	42*01	CAGSGGGSQGNLIF	FLU α58	2		
		Single												
		FLUMP58_T1D-1_4	19*01	2-1*01	2*01	CASSIRSLDEQFF	FLU β55	25*01	42*01	CPVTLSLAYSPIINF	FLU α59	1	TCRα CDR3 previously described by: Naumov et al., 2008; TCRα CDR3 shared with HC2	
		FLUMP58_T1D-1_5	19*01	2-1*01	1*01	CASSFTKDYSTMF	FLU β56	29/DV5*01	42*01	CTSVQAL#GGSGQNLIF	FLU α60	1		
		FLUMP58_T1D-1_6	19*01	2-3*01	2*01	CAGGRKRNTQYF	FLU β57	29/DV5*01	42*01	CTSVQAL#GGSGQNLIF	FLU α60	1		
		FLUMP58_T1D-1_7	19*01	1-2*01	1*01	CASRTATHGYTF	FLU β58	3*01	36*01	CAVRDGTGANNLFF	FLU α37	1		
		FLUMP58_T1D-1_8	19*01	2-1*01	2*01	CASSELGGXANGQFF	FLU β59	3*01	37*02	CAVNRHSSNTGKLI	FLU α61	1		
		FLUMP58_T1D-1_9	19*01	2-7*01	1*01	CASSDRSSYEQYF	FLU β60	26-1*01	53*01	CIVRQLGTGAVVTIN*#F	FLU α62	1		
		FLUMP58_T1D-1_10	19*01	2-7*01	1*01	CASSTRPSYEQYF	FLU β61	8-6*02	37*02	CAVSSNTGKLI	FLU α63	1		
		FLUMP58_T1D-1_11	19*01	2-3*01	1*01	CASSGRPTETQYF	FLU β62	25*01	42*01	CAVSYGGGQGNLIF	FLU α16	1	TCRα CDR3 shared with HC1;	
		FLUMP58_T1D-1_12	19*01	2-1*01	2*01	CAGSVLRGGRNERFF	FLU β63	36/DV7*02	22*01	CAVED#ISSGARQLTF	FLU α64	1		
		FLUMP58_T1D-1_13	27*01	2-2*01	1*01	CASLIFPGELFF	FLU β64	8-4*03	45*01	VL#GGGADGLTF	FLU α65	1		
		FLUMP58_T1D-1_14	27*01	1-5*01	1*01	CASSLMGQGINQPHF	FLU β65	17*01	23*01	CARSRNKQGGIFFF	FLU α66	1		
		FLUMP58_T1D-1_15	3-2*01	2-3*01	2*01	CASRGA*RRGVRR#F	FLU β66	8-2*01	52*01	VL*V#AGGTSYGKLI	FLU α67	1		
		FLUMP58_T1D-1_16	4-3*01	1-4*01	1*01	CASSOEWGINEKLF	FLU β67	25*01	23*01	CAGSPIYNQGGKLI	FLU α68	1		
		FLUMP58_T1D-1_17	7-8*01	2-7*01	2*01	CATPTNLGGGGNYF	FLU β68	29/DV5*01	52*01	VQDQLGY#GGTSYGKLI	FLU α69	1		
		FLUMP58_T1D-1_18	19*01	2-3*01	2*01	CASSGGSKNYAVF	FLU β69	29/DV5*01	42*01	CAASAGGGSQGNLIF	FLU α56	1		
		FLUMP58_T1D-1_19	19*01	1-5*01	1*01	CASSIHGANQPQHF	FLU β70	23/DV6*01	33*01	CAASARSMDSNYQLIW	FLU α70	1		
		FLUMP58_T1D-1_20	19*01	1-5*01	1*01	CASSIRGANQPQHF	FLU β71	23/DV6*01	33*01	CAASARSMDSNYQLIW	FLU α70	1		
		FLUMP58_T1D-1_21	19*01	1-1*01	1*01	CAGSVTGALGTEAFF	FLU β72	17*01	52*01	CATDDHAGGTSYGKLI	FLU α71	1		
		FLUMP58_T1D-1_22	19*01	2-3*01	1*01	CASRKRGTAEQFF	FLU β73	3*01	42*01	CASPGGGGQGNLIF	FLU α72	1		
		FLUMP58_T1D-1_23	19*01	2-7*01	1*01	CASRTRSAYEQYF	FLU β74	27*01	42*01	CAGGGGQGNLIF	FLU α31	1	TCRα CDR3 previously described by: Gil et al., 2015; Valkenburg et al., 2016; TCRα CDR3 shared with HC2	
		FLUMP58_T1D-1_24	19*01	1-5*01	1*01	CASSIHGANQPQHF	FLU β70	23/DV6*01	33*01	CAAGGGAWLARISF	FLU α73	1		
		FLUMP58_T1D-1_25	19*01	2-7*01	1*01	CASSIRSSYEQYF	FLU β75	29/DV5*01	42*01	CAASATPYGGGQGNLIF	FLU α74	1		
		FLUMP58_T1D-1_26	4-2*01	1-2*01	1*01	CASSPGTPTYGYTF	FLU β76	8-2*01	30*01	CAVSDLIIGDDKLI	FLU α75	1		
		FLUMP58_T1D-1_27	19*01	2-3*01	1*01	CASSPRSTDQYF	FLU β77	25*01 F	42*01	CAGASGGGQGNLIF	FLU α76	1	TCRα CDR3 previously described by: Gil et al., 2015; Naumov et al., 2008; TCRβ CDR3 previously described by: Lehner et al., 1995; Naumov et al., 1998; Naumov et al., 2008	
		FLUMP58_T1D-1_28	18*01 F	2-2*01	1*01	CASSQTGAELFF	FLU β78	36/DV7*02	32*02	CAVGGATNKLI	FLU α77	1		
		FLUMP58_T1D-1_29	6-5*01 F	2-5*01	1*01	CASSTLTGAETQYF	FLU β79	24*01	47*01	CAFIHLEYGNKLVF	FLU α78	1		
		FLUMP58_T1D-1_30	27*01	1-1*01	1*01	CASSTRGVSKVFF	FLU β80	14/DV4*02 F	33*01	CAMREVIHMSNYQLIR	FLU α79	1		
		FLUMP58_T1D-1_31	19*01	2-7*01	1*01	CASSIRSSYEQYF	FLU β81	26-2*01	42*01	CTPG#SQGNLIF	FLU α80	1	TCRβ CDR3 previously described by: Lehner et al., 1995, Valkenburg et al., 2016	
		FLUMP58_T1D-1_32	19*01	2-7*01	1*01	CASSIRSSYEQYF	FLU β81	36/DV7*02	45*01	CI##GGADGLTF	FLU α81	1	TCRβ CDR3 previously described by: Lehner et al., 1995, Valkenburg et al., 2016	
		NA	NA	NA	NA	NA	NA	23/DV6*01	33*01	CAEKARSMVXNYQLIW	FLU α82	1		
		NA	NA	NA	NA	NA	NA	27*01	27*01	CAGANTNAGKSTF	FLU α83	1		
		NA	NA	NA	NA	NA	NA	22*01	37*02	CAVGPSNTGKLI	FLU α84	1		
		NA	NA	NA	NA	NA	NA	8-6*01	42*01	CAVSGGNYGVXQGNLIF	FLU α85	1		
		NA	NA	NA	NA	NA	NA	8-4*03	15*01	CCEGLM#AGTALIF	FLU α86	1		
		NA	NA	NA	NA	NA	NA	36/DV7*02	45*01	CI##GGADGLTF	FLU α87	1		
		NA	NA	NA	NA	NA	NA	26-2*01	10*01	CILRDPFTGGIKFTF	FLU α88	1		
		NA	NA	NA	NA	NA	NA	26-1*01	2*01	CIVRVLGIVEVATIN*#F	FLU α89	1		
		NA	NA	NA	NA	NA	NA	3*01	8*01	CAVRDLNTGFQKLVF	FLU α90	1		
		NA	NA	NA	NA	NA	NA	26-1*01	52*01	CIVRRGGTSYGKLI	FLU α91	1		
		NA	NA	NA	NA	NA	NA	29/DV5*01	15*01	VQYYS#QAGTALIF	FLU α92	1		
		NA	NA	NA	NA	NA	NA	25*01	9*01	CAEEDDTGGFKTI	FLU α93	1		
		NA	NA	NA	NA	NA	NA	29/DV5*01	42*01	CTSVQAL#GGSGQNLIF	FLU α60	1		
		NA	NA	NA	NA	NA	NA	29/DV5*01	42*01	CTSVQAL#GGSGQNLIF	FLU α60	1		
		NA	NA	NA	NA	NA	NA	23/DV6*01	33*01	CAASARSMDSNYQLIW	FLU α70	1		
		NA	NA	NA	NA	NA	NA	3*01	36*01	CAVRDGTGANNLFF	FLU α37	1	TCRα CDR3 previously described by: Naumov et al., 2008; TCRα CDR3 shared with HC2	
		19*01	1-2*01	2*02			CAGGIGSYGYPF	FLU β82	NA	NA	NA	NA	1	
		19*01	1-2*01	1*01			CASGIGGGYYP	FLU β83	NA	NA	NA	NA	1	
		19*01	2-7*01	2*01			CASGIRSSYERYF	FLU β84	NA	NA	NA	NA	1	
		19*01	2-5*01	2*02			CASGSIEETQYF	FLU β85	NA	NA	NA	NA	1	
		19*01	2-7*01	1*01			CASGXRRXYEXF	FLU β86	NA	NA	NA	NA	1	
		19*01	2-7*01	1*01			CASRARSPNEQNF	FLU β87	NA	NA	NA	NA	1	
19*01	1-1*01	1*01			CASRATGGLGPEAFF	FLU β88	NA	NA	NA	NA	1			
19*01	1-2*01	2*02			CASRIGINGYYP	FLU β89	NA	NA	NA	NA	1			
19*01	2-7*01	1*01			CASRIRGGSEXXF	FLU β90	NA	NA	NA	NA	1			
19*01	2-7*01	1*01			CASRIRGSYEQYF	FLU β91	NA	NA	NA	NA	1			
19*01	2-5*01	2*02			CASRRKSSEAYF	FLU β92	NA	NA	NA	NA	1			
19*01	2-1*01	1*01			CASRSTGDYSTMS#F	FLU β93	NA	NA	NA	NA	1			
19*01	1-1*01	1*01			CASSGTXLNTEAFF	FLU β94	NA	NA	NA	NA	1			
19*01	1-2*01	1*01			CASSIGGGYYP	FLU β95	NA	NA	NA	NA	1			

Antigen	Donor	TCR name (clonotype)	TRBV	TRBJ	TRBD	TCRβ CDR3 sequence	TCRβ CDR3 name	TRAV	TRAJ	TCRα CDR3 sequence	TCRα CDR3 name	Number cells	Comments
FluMP58-66	T1D-1		19*01	2*7*01	1*01	CASSIRGSYEQYF	FLU β96	NA	NA	NA		1	
			19*01	2*7*01	2*01	CASSIRPSYERYF	FLU β97	NA	NA	NA		1	
			19*01	2*7*01	2*01	CASSIRSSYERYF	FLU β98	NA	NA	NA		1	
			27*01	1*6*02	1*01	CASSLSLGDRLXPYNSPXXF	FLU β99	NA	NA	NA		1	
			28*01	2*7*01	1*01	CASSSWTGXXIXX#	FLU β100	NA	NA	NA		1	
			19*01	1*2*01	1*01	CASSTGLGYTF	FLU β101	NA	NA	NA		1	
			19*01	1*2*01	1*01	CASSTGLGYPF	FLU β102	NA	NA	NA		1	
			7*8*03	2*7*01	1*01	CASSTSLGGGARQYF	FLU β103	NA	NA	NA		1	
			24*1*01	2*7*01	1*01	CATRKFGRKD#EQYF	FLU β104	NA	NA	NA		1	
			29*1*01	2*6*01	1*01	CSVDROG#SGANVLT	FLU β105	NA	NA	NA		1	
			19*01	2*7*01	2*01	CVCRXGGSYERDF	FLU β106	NA	NA	NA		1	
			19*01	1*2*01	NA	CVGRKGRDGYPF	FLU β107	NA	NA	NA		1	
			23*1*01	2*7*01	NA	CXRPXXGGGXTLPPTGP	FLU β108	NA	NA	NA		1	
			19*01	2*5*01	NA	CXSSVRSSYEQYF	FLU β109	NA	NA	NA		1	
			19*02	2*7*01	1*01	CXSIIRPXXQXF	FLU β110	NA	NA	NA		1	
			19*03	1*2*01	NA	CAGXKGSXPTL	FLU β111	NA	NA	NA		1	
			19*04	1*5*01	2*02	CASGNGDPLXF	FLU β112	NA	NA	NA		1	
			19*05	2*7*01	2*01	CASSRSPYEQYF	FLU β113	NA	NA	NA		1	
			19*06	2*1*01	1*01	CAGRVGSAPAXSC	FLU β114	NA	NA	NA		1	
			27*01	2*7*01	2*01	CAGXFGGSSKQXF	FLU β115	NA	NA	NA		1	
			23*1*01	2*7*01	NA	CASAKXSGRNSLPXXGX	FLU β116	NA	NA	NA		1	
			5*1*01	2*1*01	1*01	CASCLGGGSYNEQFF	FLU β117	NA	NA	NA		1	
			19*01	1*2*01	1*01	CASGIGGYGYPF	FLU β118	NA	NA	NA		1	
			27*01	2*5*01	1*01	CASSFGGAETQYF	FLU β119	NA	NA	NA		1	
			19*01	2*7*01	1*01	CASSGRSPYEQDF	FLU β120	NA	NA	NA		1	
			19*01	1*2*01	NA	CASSIGYGYTF	FLU β121	NA	NA	NA		1	
			19*01	1*5*01	2*02	CASSISLNPQHF	FLU β122	NA	NA	NA		1	
			19*01	1*5*01	2*01	CASSKRSNPPQHF	FLU β123	NA	NA	NA		1	
			28*01	2*1*01	2*01	CASSLPDLASGRKTRSYNEQFF	FLU β124	NA	NA	NA		1	
			28*01	2*7*01	1*01	CASSSWTG#SYEQYF	FLU β125	NA	NA	NA		1	
			28*01	2*7*01	1*01	CASSSWTGGPTSS#	FLU β126	NA	NA	NA		1	
			19*01	2*5*01	1*01	CASSTRSGETQYF	FLU β127	NA	NA	NA		1	
			19*01	2*7*01	NA	CASSVRSSYEQYF	FLU β128	NA	NA	NA		1	TCRβ CDR3 previously described by: Valkenburg et al. 2016
			19*01	1*2*01	1*01	GASSIGFYTF	FLU β129	NA	NA	NA		1	
			19*01	2*7*01	1*01	CASSIRGSYEQYF	FLU β96	NA	NA	NA		1	
	19*01	2*7*01	1*01	CASSIRPSYEQYF	FLU β27	NA	NA	NA		1	TCRβ CDR3 shared with HC2		
	19*01	1*2*01	1*01	CASSTGLGYPF	FLU β130	NA	NA	NA		1			
	19*01	1*2*01	2*02	CASRIGYGYTF	FLU β131	NA	NA	NA		1			
	19*01	2*7*01	1*01	CASSIRSSYEQYF	FLU β81	NA	NA	NA		1	TCRβ CDR3 previously described by: Lehner et al., 1995, Valkenburg et al., 2016		
	19*01	1*2*01	2*02	CASSTGSYGYTF	FLU β132	NA	NA	NA		1	TCRβ CDR3 previously described by: Lehner et al., 1995; Naumov et al., 1998		
	19*01	2*7*01	2*02	CASSIGSYGYTF	FLU β133	NA	NA	NA		1	TCRβ CDR3 previously described by: Naumov et al., 1998, Valkenburg et al. 2016		
	19*01	2*1*01	2*01	CASSRSAIEQFF	FLU β134	NA	NA	NA		1			
	19*02	2*7*02	2*02	CASSIRSAIEQYF	FLU β75	NA	NA	NA		1			
	19*01	2*1*01	2*01	CASSIRSLDEQFF	FLU β55	NA	NA	NA		1			
	7*2*01	2*7*01	2*01	CASSTSLGGGRQSF	FLU β135	NA	NA	NA		1			

Antigen	Donor	TCR name (clonotype)	TRBV	TRBJ	TRBD	TCRβ CDR3 sequence	TCRβ CDR3 name	TRAV	TRAJ	TCRα CDR3 sequence	TCRα CDR3 name	Number cells	Comments	
IGRP265-273	T1D-1												Enriched	
		IGRP265-273_T1D-1_1	3*1*01	2*4*01	1*01	CASSQDRWDVMSKNIQYF	IGRP β1	25*01	53*01	CAGLDGSGGSNYKLT	IGRP α1	299	TCRα CDR3 shared with T1D-3	
		IGRP265-273_T1D-1_2	10*3*01	1*2*01	1*01	CAISEMILIRGLANYGYPF	IGRP β2	29/DV5*01	53*01	CAASGGSNYKLT	IGRP α2	20	TCRα CDR3 shared with T1D-2	
		IGRP265-273_T1D-1_3	10*3*01	1*2*01	2*02	CAISDRFMREMTYGYPF	IGRP β3	29/DV5*01	53*01	CAASGGSNYKLT	IGRP α2	11	TCRα CDR3 shared with T1D-2	
		IGRP265-273_T1D-1_4	24*1*01	2*1*01	2*01	CATSDPLIKGLAEYNEQYF	IGRP β4	29/DV5*01	53*01	CAASGGSNYKLT	IGRP α2	6	TCRα CDR3 shared with T1D-2	
		IGRP265-273_T1D-1_5	6*2*01	2*7*01	1*01	CASGTLIRGKGYERYF	IGRP β5	29/DV5*01	53*01	CAASGGSNYKLT	IGRP α2	5	TCRα CDR3 shared with T1D-2	
		IGRP265-273_T1D-1_6	3*1*01	2*4*01	1*01	CASSQDRWDVMSKNIQYF	IGRP β1	17*01	17*01	CATLCPG#NKLTF	IGRP α3	4		
		IGRP265-273_T1D-1_7	3*1*01	2*4*01	1*01	CASGDGLAGKITGELFF	IGRP β6	25*01	53*01	CAGLDGSGGSNYKLT	IGRP α1	3	TCRα CDR3 shared with T1D-3	
		IGRP265-273_T1D-1_8	3*1*01	2*4*01	1*01	CASSQDRWDVMSKNIQYF	IGRP β1	29/DV5*01	54*01	CAASLLQGAQKLVF	IGRP α4	2		
		IGRP265-273_T1D-1_9	19*01	1*2*01	2*01	CAKKTSLGPGANYGYTF	IGRP β7	29/DV5*01	53*01	CAASGGSNYKLT	IGRP α2	2	TCRα CDR3 shared with T1D-2	
		IGRP265-273_T1D-1_10	28*01	2*7*01	1*01	CASROLIQRSSYEQYF	IGRP β8	29/DV5*01	39*01	CAASDGAGNMLTF	IGRP α5	2		
			3*1*01	2*4*01	1*01	CASSQDRWDVMSKNIQYF	IGRP β1	17*01	NA	NA		6		
														Single
		IGRP265-273_T1D-1_11	10*3*01	1*2*01	2*02	CASSGRFLREGMTYGYTF	IGRP β9	29/DV5*02	53*02	CAASGGSNYKLT	IGRP α2	1	TCRα CDR3 shared with T1D-2	
		IGRP265-273_T1D-1_12	24*1*01	2*6*01	1*01	CPLRGLPLFMGGEGP#	IGRP β10	29/DV5*05	53*05	CAASGGSNYKLT	IGRP α2	1	TCRα CDR3 shared with T1D-2	
		IGRP265-273_T1D-1_13	3*1*01	2*4*01	1*01	CASSQDRWDVMSKNIQYF	IGRP β11	8*3*01	36*01	CALQTGANLFF	IGRP α6	1		
IGRP265-273_T1D-1_14	10*3*01	1*2*01	2*01	CAISDRFMREMTYGYTF	IGRP β12	29/DV5*01	53*01	VQQAQ#SNYKLT	IGRP α7	1				
IGRP265-273_T1D-1_15	10*3*01	2*7*01	1*01	CAISES*GYEQYF	IGRP β13	8*3*01	43*01	CAVGEQNDMRF	IGRP α8	1				
IGRP265-273_T1D-1_16	27*01	2*2*01	2*01	CASSDGLAGK#ANTGELFF	IGRP β14	17*01	17*01	CATLC#AGNKLT	IGRP α9	1				
IGRP265-273_T1D-1_17	28*01	2*7*01	2*01	CASSSVIAGGDYEQNF	IGRP β15	29/DV5*01	21*01	CAASVGSFNKIFYF	IGRP α10	1				
IGRP265-273_T1D-1_18	3*1*01	2*4*01		CASRODRWEKMGQNIIRF	IGRP β16	25*01	53*01	CAGLDGSGGSNYKLT	IGRP α1	1	TCRα CDR3 shared with T1D-3			

Antigen	Donor	TCR name (clonotype)	TRBV	TRBJ	TRBD	TCRβ CDR3 sequence	TCRβ CDR3 name	TRAV	TRAJ	TCRα CDR3 sequence	TCRα CDR3 name	Number cells	Comments			
IGRP265-273	T1D-1	IGRP265-273_T1D-1_19	6-5*01	2-1*01	2*01	CASSPVLGLDEQFF	IGRP β17	17*01	20*01	CAAFRSNDYKLSF	IGRP α11	1				
		IGRP265-273_T1D-1_20	24-1*01	2-1*01	1*01	CATSDLPIYIGTRLNEQFF	IGRP β18	8-4*01	53*01	CAVSADSGGSNYKLTFF	IGRP α12	1				
			NA	NA	NA	NA		29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	1	TCRα CDR3 shared with T1D-2			
			NA	NA	NA	NA		25*01	53*01	CAGLGDSGGSNYKLTFF	IGRP α1	1	TCRα CDR3 shared with T1D-3			
			10-3*01	1-2*01	2*02	CAISDRFMRXXTNGYYPF	IGRP β19	NA	NA	NA		1				
			27*01	2-2*01	2*02	CASGHFLAGKIPXGL#F	IGRP β20	NA	NA	NA		1				
			27*01	2-2*01	2*01	CASSDGLAGKREHRG##FF	IGRP β21	NA	NA	NA		1				
			28*01	2-7*01	1*01	CASRVLIKKSSYF*F	IGRP β22	NA	NA	NA		1				
			27*01	2-2*01	2*01	CASSDGLAGK#ANTGELFF	IGRP β14	NA	NA	NA		1				
			6-5*01	2-3*01	2*02	CASSYVAPRFQDTQ#F	IGRP β23	NA	NA	NA		1				
			3-1*01	2-4*01	2*01	CAXGXERWVSVKNIQYF	IGRP β24	NA	NA	NA		1				
			28*01	2-7*01	1*01	CASRGLIIQRSSYEYQF	IGRP β8	NA	NA	NA		1				
		T1D-2												Enriched		
				IGRP265-273_T1D-2_1	30*01	1-2*01	1*01	CAWGVLFIGRVDGYGYTF	IGRP β25	29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	5	TCRα CDR3 shared with T1D-1	
				IGRP265-273_T1D-2_2	28*01	2-7	2*01	CASGSHHISGGATXR#	IGRP β26	29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	2	TCRα CDR3 shared with T1D-1	
				IGRP265-273_T1D-2_3	3-1*01	1-2*01	1*01	CASSQEVMTALQPDYGYTF	IGRP β27	29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	3	TCRα CDR3 shared with T1D-1	
					NA	NA	NA	NA		29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	71	TCRα CDR3 shared with T1D-1	
															Single	
				IGRP265-273_T1D-2_4	28*01	2-3*01	2*01	CAKSSPXISGITDXRYF	IGRP β28	29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	1	TCRα CDR3 shared with T1D-1	
				IGRP265-273_T1D-2_5	5-8*01	1-2*01	1*01	CASSAVIRGLDMWCYTF	IGRP β29	29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	1	TCRα CDR3 shared with T1D-1	
IGRP265-273_T1D-2_6	28*01			2-3*01	2*01	CASSPFFRGIIXDXGYF	IGRP β30	29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	1	TCRα CDR3 shared with T1D-1			
IGRP265-273_T1D-2_7	10-3*01			1-2*01	1*01	CAISDLITGGDNYGYTF	IGRP β31	29*DV5*01	53*01	CAASGGSNYKLTFF	IGRP α2	1	TCRα CDR3 shared with T1D-1			
IGRP265-273_T1D-2_8	19*01	2-7*01	2*01	CASRSSDPYEQYF	IGRP β32	8-1*01	34*01	CAVISYNTDKLIF	IGRP α13	1						
IGRP265-273_T1D-2_9	6-1*01	1-2*01	1*01	CASSEVNRGNGYTF	IGRP β33	26-1*01	37*02	CISP*SGSNTGKLIFF	IGRP α14	1						
IGRP265-273_T1D-2_10	6-1*01	1-2*01	2*02	CASSPRXKANYGYTF	IGRP β34	3*01	26*01	CAVRDFSDNYGQNFVF	IGRP α15	1						
IGRP265-273_T1D-2_11	4-2*01	2-2*01	2*02	CASSQGVIESGELFF	IGRP β35	26-1*01	39*01	CIXXL*NDIGENMFLI	IGRP α16	1						
IGRP265-273_T1D-2_12	5-8*01	1-2*01	1*01	CASSSAVIRGLDGGYTF	IGRP β36	26-1*01	29*01	CIVRVA#SGNTPLVF	IGRP α17	1						
	27*01	1-6*02	1*01	CASNTGLRFTFP#F	IGRP β37	NA	NA	NA		1						
	2*01	1-5*01	1*01	CASSEGAIGPQHF	IGRP β38	NA	NA	NA		1						
	7-8*01	2-7*01	1*01	CASSLGDNGGYEQYF	IGRP β39	NA	NA	NA		1						
	28*01	1-5*01	2*01	CASSLFSXGGGXQPQHF	IGRP β40	NA	NA	NA		1						
	12-3*01	1-2*01	1*01	CASSLWVAGNGSTF	IGRP β41	NA	NA	NA		1						
	4-2*01	2-2*01	2*02	CASSQDPGXGELFF	IGRP β42	NA	NA	NA		1						
	28*01	2-7*01	2*01	CASSSHHISGGXTSR#F	IGRP β43	NA	NA	NA		1						
	28*01	2-3*01	1*01	CASSPFFHIEIXDTQXF	IGRP β44	NA	NA	NA		1						
T1D-3												Enriched				
		IGRP265-273_T1D-3_1	3-1*01	2-2*01	1*01	CASSQDHRVMDLADGELFF	IGRP β45	25*01	53*01	CAGLGDSGGSNYKLTFF	IGRP α1	20	TCRα CDR3 shared with T1D-1			
			NA	NA	NA	NA		26-1*03	54*01	CIAQGAQKLVF	IGRP α18	7				
			3-1*01	2-2*01	1*01	CASSQDHRVMDLADGELFF	IGRP β45	NA	NA	NA		23				
													Single			
		IGRP265-273_DM3_2	6-1*01	2-7*01	1*01	CAIWKRV#YEYQYF	IGRP β46	8-6*02	13*02	CAVTRW#GGYQVTF	IGRP α19	1				
		IGRP265-273_DM3_3	7-8*01	2-5*01	1*01	CASRIWYIRNEETQYF	IGRP β47	25*01	47*02	CAG#YGNKLVF	IGRP α20	1				
		IGRP265-273_DM3_4	29-1*01	1-2*01	1*01	CSVPTGEGYGYTF	IGRP β48	35*01	28*01	CAXSGGGSYQLTF	IGRP α21	1				
		IGRP265-273_DM3_5	5-6*01	2-7*01	1*01	CASSLDRAIGVTYEQYF	IGRP β49	8-2*01	32*02	CVVSDGYGGATNKLIF	IGRP α22	1				
		IGRP265-273_DM3_6	5-6*01	2-1*01	2*01	CASSYGLAEQFF	IGRP β50	8-6*02	21*01	CALPP#YFNKFF	IGRP α23	1				
IGRP265-273_DM3_7	20-1*01	2-6*01	1*01	CSASASLTSGANVLTFF	IGRP β51	26-1*01	54*01	CIAQGAQKLVF	IGRP α18	1						
IGRP265-273_DM3_8	6-1*01	2-1*01	2*01	CARRSRGENNGGVF	IGRP β52	27*01	23*01	CAGGLIYNQEGKLIFF	IGRP α24	1						
IGRP265-273_DM3_9	6-6*01	2-7*01	NA	CASSYQHEQYF	IGRP β53	8-3*01	45*01	CAGRLVYGGADALTF	IGRP α25	1						
	NA	NA	NA	NA		4*01	42*01	CLAGEWYGGSQGNLIF	IGRP α26	1						
	NA	NA	NA	NA		26-1*01	39*01	CIVRVAMGAGNMLTF	IGRP α27	1						
	NA	NA	NA	NA		17*01	45*01	CATDGAAGDGLTF	IGRP α28	1						
	NA	NA	NA	NA		8-4*05	39*01	CVVSLNAGNMLTF	IGRP α29	1						
	2*01	1-5*01	2*01	CASSDGGGGQPXF	IGRP β54	NA	NA	NA		1						
	6-1*01	2-2*01	1*01	CASSEDRTGELFF	IGRP β55	NA	NA	NA		1						
	6-2*01	2-1*01	1*01	CASSLGRINEQFF	IGRP β56	NA	NA	NA		1						
	4-1*01	2-7*01	1*01	CAXGKKGTPX##F	IGRP β57	NA	NA	NA		1						
	19*01	1-2*01	2*01	FLGARMXGKMLTINTP#	IGRP β58	NA	NA	NA		1						
	6-5*01	1-1*01	1*01	CAIREDSVFFF	IGRP β59	NA	NA	NA		1						
	28*01	1-4*01	1*01	CASRPITGLKLF	IGRP β60	NA	NA	NA		1						
	3-1*01	2-3*01	1*01	CASSHGKTXF	IGRP β61	NA	NA	NA		1						
	12-3*01	2-2*01	2*01	CASSLGGGLFF	IGRP β62	NA	NA	NA		1						
	4-2*01	2-6*01	1*01	CASSQROGSGANVLTFF	IGRP β63	NA	NA	NA		1						
	20-1*01	2-7*01	1*01	CSARGSSYEQYF	IGRP β64	NA	NA	NA		1						
	27*01	2-3*01	2*01	CARSRGXKTXQ#F	IGRP β65	NA	NA	NA		1						
	4-2*01	2-7*01	2*01	CASXPRESSEXRF	IGRP β66	NA	NA	NA		1						
T1D-4												Single				
		IGRP265-273_T1D-4_1	6-5*01	2-2*01	1*01	CASVGPYGTGELFF	IGRP β67	8-2*01	48*01	CAVS#SNFNGEKLTF	IGRP α30	1				
		IGRP265-273_T1D-4_2	27*01	2-4*01	1*01	CASREGSYPKNIQYF	IGRP β68	8-6*01	29*01	CKAPLVF	IGRP α31	1				
			NA	NA	NA	NA		3*01	31*01	CAVRLGGARLMF	IGRP α32	1				
	NA	NA	NA	NA		2*01	12*01	VL*#DSSYLKIF	IGRP α33	1						

Antigen	Donor	TCR name (clonotype)	TRBV	TRBJ	TRBD	TCRβ CDR3 sequence	TCRβ CDR3 name	TRAV	TRAJ	TCRα CDR3 sequence	TCRα CDR3 name	Number cells	Comments	
IGRP265-273	T1D-4		4-1*01	2-3*01	1*01	CARXGAXRXE*PXX	IGRP β69	NA	NA	NA		1		
			4-1*01	1-1*01	1*01	CASPRFGEXAR*LLS#FF	IGRP β70	NA	NA	NA		1		
			6-1*01	1-6*02	2*01	CASRGGGSPLHF	IGRP β71	NA	NA	NA		1		
			5-5*01	1-2*01	1*01	CASSLTGTASTYGYTF	IGRP β72	NA	NA	NA		1		
		27*01	1-1*01	2*02	VPPVCV*GGTLKLF#	IGRP β73	NA	NA	NA		1			
	T1D-5													Single
		IGRP265-273_T1D-5_1	12-3*01	1-1*01	1*01	CASSWETEAEFF	IGRP β74	8-1*01	9*01	CAVMAPHTGGFKTIF	IGRP α34		1	
		IGRP265-273_T1D-5_2	6-5*01	2-3*01	2*01	CASSYSGGNRKNTQNF	IGRP β75	29/DV5*01	52*01	CAASASGGTSYGKLTIF	IGRP α35		1	
		IGRP265-273_T1D-5_3	12-3*01	1-2*01	2*01	FASRLGGSYX*TF	IGRP β76	36/DV7*02	42*01	CAAMNYGGSQGNLIF	IGRP α36		1	
			NA	NA	NA	NA		8-1*01	43*01	CAVLMDNDMRF	IGRP α37		1	
		NA	NA	NA	NA		8-2*01	33*01	CAVTRNPGDSNYQLIW	IGRP α38		1		
		6-2*01	2-1*01	2*01	CASCSTSFNEQFF	IGRP β77	NA	NA	NA			1		
		2*01	1-2*01	2*01	CASSDSIG*WLW##F	IGRP β78	NA	NA	NA			1		
		6-2*01	2-7*01	2*01	CASSNRXSFYERYF	IGRP β79	NA	NA	NA			1		
T1D-12				NA	NA	NA	NA		3*01	22*01	CADS#ARQLTF	IGRP α39	1	
			NA	NA	NA	NA		8-4*04	17*01	CAVSEIKAAGNKLTIF	IGRP α40	1		
			NA	NA	NA	NA		41*01	42*01	CAVAAGYGGSQGNLIF	IGRP α41	1		
		7-9*01	2-3*01	1*01	CASSLILGAPDTX#F	IGRP β80	NA	NA	NA			1		
T1D-13													Single	
		29-1*01	2-3*01	2*01 F	CSPTGLRDTQYF	IGRP β81	NA	NA	NA			1		
T1D RO-3			29-1*01	2-7*01	1*01 F	CSVESMDRNYEQYF	IGRP β82	NA	NA	NA		1		
													Single	
	IGRP265-273_ROTDM1_1	28*01	2-1*01	2*01	CASSPITGTSLANEQFF	IGRP β83	12-1*01	11*01	CVVKRGYSTLTF	IGRP α42		1		
	IGRP265-273_ROTDM1_2	6-2*01	2-7*01	2*01	FXGSPGTGGGKXYF	IGRP β84	6*03	11*01	CALRGGYSTLTF	IGRP α43		1		
		NA	NA	NA	NA		25*01	15*01	CAGPVHQAGTALIF	IGRP α44		1		
		NA	NA	NA	NA		12-1*01	31*01	CVGGNARLMF	IGRP α45		1		
HC5													Single	
	IGRP265-273_HC5_1	10-3*01	1-1*01	2*02	CAIRGEGNTEAFF	IGRP β86	29/DV5*01	40*01	CAASGXGTYKYIF	IGRP α46		1		
		NA	NA	NA	NA		3*01	34*01	CAVRAYLSYNTDKLIF	IGRP α47		1		
		2*01	1-2*01	2*02	CASPGGGTYGYGYPF	IGRP β87	NA	NA	NA			1		
HC8													Single	
	IGRP265-273_HC8_1	10-3*01	2-7*01	2*01	CAISDWSTYEQYF	IGRP β89	29/DV5*01	34*01	CAARVENNTAKLIF	IGRP α48		1		
	IGRP265-273_HC8_2	28*01	2-1*01	1*01	CASSLVGGXRRRSYTGQVF	IGRP β90	6*05	45*01	CALGGYSGGGADGLTF	IGRP α49		1		
		NA	NA	NA	NA		29/DV5*01	48*01	CAASDNFGNEKLTIF	IGRP α50		1		
		NA	NA	NA	NA		25*01	48*01	CAGPRSNFGNEKLTIF	IGRP α51		1		
		2*01	1-2*01	NA	CASRXSANYGYTF	IGRP β91	NA	NA	NA			1		
		27*01	2-7*01	1*01	CASSLSWGYEQYF	IGRP β92	NA	NA	NA			1		
		14*01	1-1*01	NA	CASSPRRQSLNTEAFF	IGRP β93	NA	NA	NA			1		
		10-3*01	2-7*01	1*01	CATSGTGYEQYF	IGRP β94	NA	NA	NA			1		
	HC9													Single
		NA	NA	NA	NA		29/DV5*01	53*01	CAASGSSNYHLSF	IGRP α52		1		
		NA	NA	NA	NA		29/DV5*01	29*01	CAASPPSGNTPLVF	IGRP α53		1		
HC10													Single	
		3-1*01	2-7*01	NA	CASRPLETEYDQPL	IGRP β95	NA	NA	NA			1		
		NA	NA	NA	NA		29/DV5*01	13*02	VILGV#QKVTF	IGRP α54		1		
		NA	NA	NA	NA		25*01	37*02	CAGTPSNTGKLIF	IGRP α55		1		
	6-1*01	2-1*01		CASSEFNEQFF	IGRP β96	NA	NA	NA			1			

Supplementary Table S2: Overview of samples used in the study.

Sample group	N	Sex (m/f)	Median age, y (range)	Median time after onset, y (range)	Figure(s) with data
Frequency and single cell TCR					
TCR analysis (Flu)	4	4/-	54 (31.2-63.0)		Fig. S1
Recent onset type 1 diabetes*	6	4/2	9.5 (7.4-10.2)	0.02 (0.01-0.04)	Fig.1
Healthy control children	8	4/4	10.5 (7.3-10.8)		Fig.1
Type 1 diabetes (>1 y duration)	13	4/9	34.4 (23.3-45.9)	14.3 (1.1-41.5)	Fig.1, Fig S2
Healthy (adult)	10	4/6	47.4 (24.0-60.0)		Fig. S2
TCRα NGS					
Healthy control adolescents	14	4/10	13.9 (11.7-16.5)		Fig.3, Fig. S5
Islet autoantibody positive	13	10/3	11.6 (3.9-18.7)		Fig.3, Fig. S5
Recent onset type 1 diabetes*	8	3/5	19.4 (5.3-22.9)	0.4 (0.04-0.93)	Fig.3, Fig. S5

*No overlap between patients

Supplementary Table S3: TCR gene usage and CDR3 sequence information of CD8⁺ T cell clones

Antigen	Clone name	TRBV	TRBJ	TRBD	TCR β CDR3 sequence	TRAV	TRAJ	TCR α CDR3 sequence
FluMP ₅₈₋₆₆	clone 7	6-1*01	1-5*01	1*01	CASSDFQAINQPQHF	27*01	23*01	CAGGLTYNQGGKLIF
IGRP ₂₆₅₋₂₇₃	clone 16 and clone 17	3-1*01	2-4*01	1*01	CASSQDRWDVMSKNIQYF	25*01	53*01	CAGLGDSGGSNYKLTF
IGRP ₂₆₅₋₂₇₃	clone 22 and clone 27	10-3*01	1-2*01	2*02	CAISDRFMREGMTYGYTF	29/DV5*01	53*01	CAASGGSNYKLTF

Supplementary Methods

Gene expression profiling

Gene expression profiles on single cells were examined as previously described⁶ with some modifications. cDNA was synthesized with Quanta qScript™ cDNA Supermix directly on cells. Total cDNA was pre-amplified for 16 cycles (1x 95°C 8', 95°C 45'', 49°C with 0.3°C increment/cycle 1', 72°C 1.5') and 1x 72°C 7' with the TATAA GrandMaster Mix (TATAA Biocenter, Göteborg, Sweden) in a final volume of 35 µl in the presence of primer pairs for the following genes: *CD52, CCL4, FASLG, IL7R, IFNG, CD3E, E2F1, PDCD1, TNF, PRF1, CCR7, GATA3, CCL5, IL10, IL21, GZMA, REL, EOMES, IL17F, GZMB, RGS16, TBX21, GZMH, TNFSF10, LAG3* (25nM final for each primer, see list below for primer details). Pre-amplified cDNA (10 µl) was then treated with 1.2 U Exonuclease I and expression quantified by real time PCR on the BioMark™ HD System (© Fluidigm Corporation, CA, USA) using the 96.96 Dynamic Array IFC and the GE 96x96 Fast PCR+ Melt protocol and SsoFast EvaGreen Supermix with Low ROX (BIO RAD, CA, USA) with 5 µM primers for each assay. Raw data was analyzed using the Fluidigm Real-Time PCR analysis software. Pre-processing and data analysis was conducted using KNIME 2.11.2 and RStudio Version 0.99.486 (Boston, MA, USA). Pre-processing via a linear model to correct for confounding sampling effects was conducted as previously described⁶. To model the bi-modal gene expression of single cells from T cell clones, the Hurdle model, a semi-continuous modeling framework, was applied to the pre-processed data⁷. This allowed us to assess the differential expression profiles with respect to the frequency of expression and the positive expression mean via a likelihood ratio test.

Primers used for gene expression profiling

Gene	Primer preamplification 5'	Primer preamplification 3'	Primer qPCR 5'	Primer qPCR 3'
GZMH	CAGCCATTCTCTC CTCCTGT	GAGCAGCTGTCA GCACAAAG	TCCTCCTGTTGGC CTTTCTT	GAGCAGCTGTCAG CACAAAG
TBX21	CCGTGACTGCCT ACCAGAAT	ATCTCCCCCAAG GAATTGAC	CCGTGACTGCCTA CCAGAAT	ATCTCCCCCAAGG AATTGAC
CD52	GCGCTTCCTCTT CCTCCTAC	CTGAAGCAGAAG AGGTGGATT	GCGCTTCCTCTTC CTCCTAC	CTGAAGCAGAAGA GGTGGATT
TNF	CCCAGGGACCT CTCTCTAA	TGAGGTACAGGC CCTCTGAT	CCCAGTGACAAG CCTGTAG	TGAGGTACAGGCC CTCTGAT
IL7R	GGAGCCAATGAC TTTGTGGT	CTGCAGGAGTGT CAGCTTTG	GGAGCCAATGACT TTGTGGT	CTGCAGGAGTGT AGCTTTG
CCL4	CTGTCCTGTCTCT CCTCATGC	GCTTGCTTCTTTT GGTTTGG	TAGCTGCCTTCTG CTCTCCA	GCTTGCTTCTTTG GTTTGG
EOMES	CACAAATACCAA CCCCGACT	GGGACAATCTGA TGGGATGA	CACAAATACCAAC CCCCGACT	GGGACAATCTGAT GGGATGA
TNFSF10	GACAGACCTGCG TGCTGAT	CAGCAGGGGCTG TTCATACT	CCTGCAGTCTCTC TGTGTGG	CAGCAGGGGCTGT TCATACT
CD3E	GCACTCACTGGA GAGTTCTGG	CCTCATCACCGC CTATGTTT	GCACTCACTGGAG AGTTCTGG	CCTCATCACCGCC TATGTTT
E2F1	GCCATCCAGGAA AAGGTGT	TCTGCACCTTCA GCACCTC	GCCATCCAGGAAA AGGTGT	TCTGCACCTTCA CACCTC
GZMA	TGCAAAAGACTG GGTGTGGA	TTTTTGCTTTTTT CATCAGC	TGCAAAAGACTGG GTGTTGA	TTTTTGCTTTTTCC ATCAGC
GZMB	GGTGGCTTCCTG ATACGAGA	GCTGCAGTAGCA TGATGTCCG	ACTGTTGGGGAAG CTCCATA	GCTGCAGTAGCAT GATGTCCG
IL21	TCGCCACATGAT TAGAATGC	AAGCAGGAAAAA GCTGACCA	TCGCCACATGATT AGAATGC	AAGCAGGAAAAAG CTGACCA
IFNG	CTGTTACTGCCA GGACCCAT	TGGATGCTCTGG TCATCTTT	GGTCATTCAGATG TAGCGGA	TGGATGCTCTGGT CATCTTT
LAG3	ATCACCCTTAG CGAAAGC	CTTGGCAGTGAG GAAAGACC	ATCACCCTTAGC GGAAAGC	CTTGGCAGTGAGG AAAGACC
PDCD1	GCTTCCGTGTCA CACAACCTG	GCACTTCTGCC TTCTCTCT	GCTTCCGTGTCA ACAACCTG	GCACTTCTGCCCT TCTCTCT
PRF1	AACTTTGCAGCC CAGAAGAC	GGGTGCCGTAGT TGGAGATA	ACAGCTTCAGCAC TGACACG	GGGTGCCGTAGTT GGAGATA
CCL5	CGCTGTCATCCT CATTGCTA	ACACACTTGGCG GTTCTTTC	ATCTGCCTCCCCA TATTCT	ACACACTTGGCGG TTCCTTTC
REL	ACAAATGTGAAG GGCGATCA	CCGTCTCTGCAG TCTTTTCC	GGAGCACAGCACA GACAACA	CCGTCTCTGCAGT CTTTTCC
RGS16	CACGCTTTCCTG AAGACAGA	GACCTCTTTAGG GGCCTCAC	CACGCTTTCCTGA AGACAGA	GACCTCTTTAGGG GCCTCAC
FASLG	GGGATGTTTCAG CTTTCCA	CAGAGGCATGGA CCTTGAGT	CAGAAGGAGCTG GCAGAACT	CAGAGGCATGGAC CTTGAGT
IL17F	TCCAAAAGCCTG AGAGTTGC	ATGCAGCCCAAG TTCCTACA	GCCTGTGCCAGGA GGTAGTA	ATGCAGCCCAAGT TTCCTACA
IL10	TGCTGGAGGACT TTAAGGGTTA	GCCTTGCTCTTG TTTTACAG	TTTAAGGGTTACC TGGGTTGC	GCCTTGCTCTTGTT TTACAG
GATA3	CCGCCCTACTAC GGAAACTC	TTGGAGAAGGGG CTGAGAT	CCGCCCTACTACG GAAACTC	TTGGAGAAGGGGC TGAGAT
CCR7	CAATGAAAAGCG TGCTGGT	ATAGGGAGGAAC CAGGCTTT	GTGGTGGCTCTCC TTGTCAT	ATAGGGAGGAACC AGGCTTT

References

- 1 Valkenburg, S. A. *et al.* Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 4440-4445, doi:10.1073/pnas.1603106113 (2016).
- 2 Gil, A., Yassai, M. B., Naumov, Y. N. & Selin, L. K. Narrowing of human influenza A virus-specific T cell receptor alpha and beta repertoires with increasing age. *Journal of virology* **89**, 4102-4116, doi:10.1128/JVI.03020-14 (2015).
- 3 Naumov, Y. N. *et al.* Multiple glycines in TCR alpha-chains determine clonally diverse nature of human T cell memory to influenza A virus. *J Immunol* **181**, 7407-7419 (2008).
- 4 Lehner, P. J. *et al.* Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. *The Journal of experimental medicine* **181**, 79-91 (1995).
- 5 Naumov, Y. N., Hogan, K. T., Naumova, E. N., Pagel, J. T. & Gorski, J. A class I MHC-restricted recall response to a viral peptide is highly polyclonal despite stringent CDR3 selection: implications for establishing memory T cell repertoires in "real-world" conditions. *J Immunol* **160**, 2842-2852 (1998).
- 6 Bonifacio, E. *et al.* Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. *Jama* **313**, 1541-1549, doi:10.1001/jama.2015.2928 (2015).
- 7 McDavid, A. *et al.* Modeling bi-modality improves characterization of cell cycle on gene expression in single cells. *PLoS computational biology* **10**, e1003696, doi:10.1371/journal.pcbi.1003696 (2014).